Abstract
Hypoglycemia is an often underrecognized side effect of type 2 diabetes therapy. This study assessed the burden of hypoglycemia in this population in Sweden and included 309 patients aged 35 years or older and treated with insulin and/or oral antidiabetic agents. Data were gathered through patient questionnaires/interviews and chart reviews. The results showed that 115 patients (37%) reported symptoms of hypoglycemia during the preceding month. Patients with hypoglycemia were more affected by their diabetes, reported lower general health, and were more anxious about hypoglycemia than those without hypoglycemia. The direct and indirect costs of hypoglycemia per patient with hypoglycemic symptoms were estimated to be U.S. $12.9 and $14.1, respectively, for a 1-month period. The results indicate that hypoglycemia is common, and that a reduction in these symptoms, without reducing glycemic control, may improve patient well-being and possibly also reduce cost.
Similar content being viewed by others
References
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
Henriksson F, Agardh C, Berne C (2000) Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 248:387–396
Henriksson F, Jonsson B (1998) Diabetes: the cost of illness in Sweden. J Intern Med 244:461–468
Henriksson F, Agardh CD, Berne C, Bolinder J, Jonsson B (1999) Health economics analysis of diabetes is necessary. It facilitates decision-making and international comparison. Lakartidningen 96:3915–3919
UK Prospective Diabetes Study (UKPDS) Group (1993) UKPDS: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
Diabetes Control and Complications Trial Research Group (1993) DCCT: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
Koro CE, Bowlin SJ, Bourgeois N, Fedder DO (2004) Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 27:17–20
Cryer PE (1999) Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 15:42–46
Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W et al. (2003) Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26:1176–1180
Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM (2001) Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653–1659
United Kingdom Prospective Diabetes Study Group (1998) United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165–175
Yki-Jarvinen H, Haring H, Zeger S, Arbet-Engels C, Nguyen C (2005) The relationship between HbA1c fasting blood glucose (FBG) and hypoglycaemia using insulin glragine versus NPH insulin: a meta-regression analysis in type 2 diabetes. (in press)
Rosenstock J, Massi Benedetti M, Haring H, Lin Z, Salzman A (2003) Confirmed lower risk of hypoglycemia with insulin glargine versus NPH insulin: a meta-analysis of 2304 patients with type 2 diabetes. Diabetologia 46: A304
Heller SR, Amiel SA, Mansell P (1999) Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 22:1607–1611
Heller SR (1999) Diabetic hypoglycaemia. Baillieres Best Pract Res Clin Endocrinol Metab 13:279–294
Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72
Anonymous (2003) National statistics. Statistic Sweden: Stockholm
Dolan P, Roberts J (2002) Modelling valuations for EQ-5D health states: an alternative model using differences in valuations. Med Care 40:442–446
Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J (1987) Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 10:617–621
Landstingsförbundet (1999) Kostnad per intagen patient (cost per admitted patient). Stockholm County Council: Stockholm
Van der Does FE, De Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM et al. (1996) Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 19:204–210
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412
Acknowledgements
We thank Agnetha Eriksson, Lil Ragnestam, Jan Ronvall, Björn Törnkvist, Mattias Eld, Birgitta Bäckström, Annika Gudmundsson, Ola Strömstedt, Marie Balte, and Gunilla Börklund for their help with patient recruitment and data collection. The study was supported by an unrestricted grant from Aventis Pharmaceuticals, USA.
Conflict of interest:
No information supplied
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lundkvist, J., Berne, C., Bolinder, B. et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 6, 197–202 (2005). https://doi.org/10.1007/s10198-005-0276-3
Issue Date:
DOI: https://doi.org/10.1007/s10198-005-0276-3